BioMed Research International
Volume 2014 (2014), Article ID 435203, 8 pages
http://dx.doi.org/10.1155/2014/435203

Review Article

Heat Shock Protein 70 in Alzheimer’s Disease

Rui-Chun Lu,¹ Meng-Shan Tan,² Hao Wang,³ An-Mu Xie,⁴ Jin-Tai Yu,1,2 and Lan Tan1,2

¹Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, No. 5 Donghai Middle Road, Qingdao 266071, China
²Department of Neurology, Qingdao Municipal Hospital, College of Medicine and Pharmaceutics, Ocean University of China, Qingdao 266003, China
³Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao 266003, China
⁴Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao 266000, China

Received 5 February 2014; Revised 16 August 2014; Accepted 7 September 2014; Published 6 November 2014

Academic Editor: Raymond Chuen-Chung Chang

Copyright © 2014 Rui-Chun Lu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Alzheimer’s disease (AD) is the most common neurodegenerative disease that caused dementia which has no effective treatment. Growing evidence has demonstrated that AD is a “protein misfolding disorder” that exhibits common features of misfolded, aggregation-prone proteins and selective cell loss in the mature nervous system. Heat shock protein 70 (HSP70) attracts extensive attention worldwide, because it plays a crucial role in preventing protein misfolding and inhibiting aggregation and represents a class of proteins potentially involved in AD pathogenesis. Numerous studies have indicated that HSP70 could suppress the progression of AD with in vitro and in vivo experiments. Thus, targeting HSP70 and the related compounds might represent a promising strategy for the treatment of AD.

1. Introduction

Alzheimer’s disease (AD) is the major cause of late-life brain failure. In the current study, the data forecasted that one new case of AD is expected to develop every 33 seconds by 2050 [1]. Lost wages and healthcare expenses related to AD patients and caregivers which had been forced to be provided by families were very high [2]. Then, all efforts to find an effective disease-modifying treatment were significant. Even modest advances in therapeutic and preventive strategies that lead to small delays in the onset and progression of AD can significantly reduce the global burden of this disease [1]. Finding an effective disease-modifying treatment depends on the pathomechanistic understanding of AD. The striking pathological characteristics of AD brains are the presence of senile plaques, neurofibrillary tangles, and neuronal loss. Growing evidence has demonstrated that AD is “protein misfolding disorders” that exhibit common features of misfolded, aggregation-prone proteins and selective cell loss in the mature nervous system. A complicated array of molecular events has been implicated in the pathogenesis of AD.

Heat shock proteins (HSPs) are a class of molecular chaperones that bind with nonnative proteins and assist them to acquire native structure and thus prevent misfolding and the aggregation process during the conditions of stress [3]. HSPs have been classified into families on the basis of molecular weight including HSP100, HSP90, HSP70, HSP60, HSP40, and HSP27. Different classes of HSPs play a diverse role in influencing proper protein assembly, folding, and translocation. HSP70, HSP60, and HSP27 prevent protein aggregation and help protein folding. HSP100 releases proteins from aggregates. HSP90 plays a cardinal role in maturation and activation of number of proteins. Experimental and other indirect evidence suggested that HSPs had shown up as critical regulators of neurodegenerative processes correlated with protein misfolding in the brains of AD patients [4–6]. Therefore, HSPs are expected to have strong potential as therapeutic agents in suppressing or curing AD. HSP70 (heat shock protein 70 kDa) is an important part of molecular chaperones, which is the most conserved one and is found in almost all the intracellular compartments. HSP70 protects proteins from misfolding and assists in the refolding and reactivation of damaged proteins [7–9]. Recent studies have shown the evidence that HSP70 might have attempted to prevent aggregate formation in cells and thus suppress AD conditions [10]. HSP70 overexpression effectively protected neurons in various animal models and cellular models of AD to exert therapeutic effect [11, 12]. Therefore, these findings prompted us to investigate a potential pharmacological role of HSP70 in AD, which might bring the hope of conquering AD eventually. In this paper, we will review the current status of experimental evidence linking HSP70 function to AD pathogenesis and pharmacological therapeutics of modulating HSP70 in AD treatment.

2. Biochemical Characteristics of HSP70

HSP70 is the most structurally and functionally conserved proteins in HSPs. HSP70 is the most ubiquitous class of ATP-dependent chaperone protein that exerts a cytoprotective effect under a number of different conditions, which plays a central role in the cellular protein quality control and degradation systems [7, 10, 13]. In humans, the HSP70 multigene family performs function on nonnative polypeptides fueled by ATP binding and hydrolysis [14]. HSP70 binds to protein substrates to assist with their folding, degradation, transport, regulation, and aggregation prevention [13, 15–18]. They carry out these activities depending on their unique molecular structure.

HSP70 consists of two highly conserved domain structures: a 45 kDa N-terminal nucleotide binding domain (NBD) and a 25 kDa C-terminal substrate binding domain (SBD), which undergo reciprocal allosteric interactions induced by ligand binding [19]. The NBD is structurally similar to actin and hexokinase, and it consists of two lobes, each containing two subdomains [20]. These lobes form a cleft that binds ATP with a nucleotide binding cassette that is related to those in hexokinase and actin [20]. The SBD consists of a β-sandwich subdomain and an α-helical lid with the substrate binding site located in the β-sandwich subdomain [18]. Both the NBD and the SBD are critical for chaperone function, which are connected by a short flexible linker [19]. As one of molecular chaperones, HSP70 has multiple responsibilities during normal growth. It assists in the folding of newly synthesized proteins [13, 21, 22], the subcellular transport of proteins and vesicles [23], the formation and dissociation of complexes [24], and the degradation of unwanted proteins [25]. HSP70 which carries out these widely divergent functions arises from three different conformations. HSP70 adopts three different conformations, one in the absence of nucleotide, one with ADP bound, and one with ATP bound. Many of the functions of HSP70 depend on crosstalk between the SBD and NBD, and ATP influences substrate binding [26]. Nonnative substrates with exposed hydrophobic stretches within an accessible polypeptide backbone associate transiently with HSP70 via its SBD. ATP binding to the NBD triggers opening of the SBD binding pocket, decreasing affinity for polypeptide substrates, and accelerating both on and off rates. Reciprocally, substrate binding induces ATP hydrolysis, “closing” the SDB and thus stabilizing the substrate-HSP70 complex [27, 28]. It is this cycle of rapid but controlled binding and release of the substrate that fosters folding and assembly with partner proteins while preventing aggregation of substrates [29]. HSP70 also is essentially a protein unfolding machine, which binds and releases stretches of hydrophobic amino acids in a regulated, ATP-hydrolysis-driven cycle [30]. A global conformational change is triggered by ATP binding that expels the bound substrate; conversely, substrate binding triggers a conformational change that stimulates the hydrolysis of ATP. ATP hydrolysis in HSP70 is thought to be a major determinant of chaperone function. Cochaperones regulated their interactions with nucleotides and substrate proteins [31]. Thus, HSP70s are part of a multiprotein complex that utilizes coordinated ATPase activity and multiple cochaperone partners to shape interactions with misfolded substrates [32]. For these reasons, recent studies have investigated the fact that HSP70s have emerged as critical regulators of proteins associated with neurodegenerative disease pathologies, acting as a potential drug target.

3. HSP70 in the Pathogenesis of AD

3.1. HSP70 Plays Cytoprotective Roles in AD by Inhibition of Aβ Oligomerization

Abundant extraneuronal deposit of amyloid-beta (Aβ) is the major pathological hallmark and plays an early important pathologic role in the development of AD. Self-assembly of Aβ produces a number of distinctive structures, such as dimmers, oligomers, unstructured aggregates, and characteristic amyloid fibrils. Oligomers are believed to be the most neurotoxic and important in the development of AD [33, 34]. Many previous studies widely accepted that Aβ aggregates trigger a series of downstream events such as plaque deposition, tau hyperphosphorylation, inflammation, loss of synaptic structure and function, and death of susceptible neurons, which was deemed as “amyloid cascade hypothesis” [33, 35–37]. Theoretically, HSP70 suppresses the aggregation of Aβ to impede the pathological process of AD. Overexpression of HSP70 which inhibits the aggregation of Aβ and ameliorates the corresponding disease symptoms had been widely accepted [6, 9]. What is the molecular mechanism used by HSP70 to inhibit Aβ self-assembly? Current models suggest that HSP70 would recognize the oligomers and modify their conformation. Exposed hydrophobic regions in oligomers are “flags” to trigger HSP70 recognition and subsequent reorganization [11].

3.2. HSP70 Plays Cytoprotective Roles in AD by Enhancing the Clearance of Aβ

Aβ is widely considered to be the major toxic agent in the pathogenesis of AD. It is undeniable that enhancing the clearance of Aβ could suppress the progression of AD. HSP70 overexpression effectively protecting neurons from intracellular accumulation of Aβ through promoting the clearance of Aβ had been reported in a number of studies [9]. Aβ is cleared from the brain through enzyme mediated degradation, phagocytosis by microglia and astrocytes, and transport into the blood and lymph nodes. HSP70 is attributable to the stimulation of Aβ clearance through upregulation of expression of insulin degrading enzyme (IDE) and TGF-β1. IDE is an Aβ-degrading enzyme that motivates the clearance of Aβ. TGF-β1 as a key cytokine regulating the response of the brain to injury and inflammation has also been suggested to suppress the progression of AD. TGF-β1 stimulates Aβ clearance through activation of phagocytic microglia.

3.3. HSP70 Plays Cytoprotective Roles in AD by Restoring Tau Homeostasis

Neurofibrillary tangles (NFTs) composed of aggregates of hyperphosphorylated forms of the protein tau are known to be another major histopathological character in AD. Tau protein is the major neuronal microtubule-associated protein (MAP) and plays a central role in maintenance and stabilization of microtubules within axons in AD. Tau homeostasis is regulated by its expression, phosphorylation, and turnover. Tau homeostasis is disrupted, leading to hyperphosphorylation and accumulation of intracellular aggregates [38]. To date, more evidence suggests that aggregation and accumulation of the microtubule-associated protein tau are associated with cognitive decline and neuronal degeneration in AD [39, 40]. Conformational changes of tau result in its disassociation from the microtubule and self-association into aggregates. Those aggregates are the toxic form of tau which is believed to be responsible for AD pathogenesis [41]. A number of studies have suggested that neuronal and cognitive defects of AD with tauopathy can be reversed by restoring tau normal homeostasis. Understanding how to keep balance of tau homeostasis may enable identification of potential mechanisms for enhancing clearance of pathological forms of tau. Tau homeostasis is normally controlled through the action of molecular chaperones, such as HSP70. HSP70 keenly draws more and more attention of the researchers because of its potential therapeutic role in regulation of tau homeostasis. It was confirmed that HSP70 might promote tau binding to microtubules and implicate blocking tau aggregation and promoting its degradation, thereby preventing tauopathy [42–47]. HSP70 directly inhibits tau aggregation by a mechanism involving preferential associations with soluble, monomeric, and prefibrillar oligomeric tau species [48]. HSP70 assists these combinations being degraded by the ubiquitin-proteasome and autophagy system. In addition, HSP70 dramatically affects tau homeostasis by its highly homologous variants disparate capacity to clear tau. HSP70 includes the inducible form of HSP70 which is termed heat shock protein 72 (HSP72) and the constitutively expressed form of HSP70 is termed heat shock cognate 70 protein (HSC70). HSP72 and HSC70 caused distinct and even opposing effects on tau’s function and stability. HSP72 can facilitate tau degradation; HSC70 actually slows tau clearance, particularly after microtubule disruption. In cellular models, inhibitors of the ATPase activity of HSP70 also have been shown to promote tau turnover and restore its homeostasis [49].

3.4. HSP70 Plays Cytoprotective Roles in AD by Inhibition of Neuronal Apoptosis

Studies on postmortem tissues provide morphological and biochemical evidence that some neurons degenerate via apoptotic mechanisms in AD. One of the most momentous findings in AD brain is the large number of neuronal losses developed by pervasive DNA damage which leads to apoptosis. Many conditions accumulate in the brain that are capable of inducing apoptosis and that place neurons at continued risk. In vivo and in vitro studies have shown that Aβ accumulation caused neuronal dysfunction and synaptic and neuronal loss [50]. Neuronal apoptosis also readily initiated by oxidative insults was known to occur in AD brain. Under some conditions, glutamate and other excitatory amino acids which initiated excitotoxic damage can activate apoptosis in the development of AD. These factors may act synergistically. For example, when subthreshold levels of Aβ are coupled with subthreshold levels of excitotoxins or oxidative stress, neuronal loss is significant. Protective mechanisms probably serve to delay degeneration and maintain neurons function in AD. Mailhos et al. first confirmed that HSP70 overexpression attenuates thermal stress-induced neuronal death [51]. On the basis of these previous data, studies showed that HSP70 modulates both Apaf-1 caspase-dependent and AIF caspase-independent pathways resulting in attenuation of apoptosis and ultimately inhibition of neuronal cell death [52] (Figure 1).

Figure 1: HSP70 plays cytoprotective roles in AD. (1) HSP70 recognizes Aβ oligomers and inhibits Aβ self-assembly; (2) HSP70 modulates both Apaf-1 caspase-dependent and AIF caspase-independent pathways resulting in attenuation of apoptosis; (3) HSP70 promotes tau binding to microtubules; (4) HSP70 directly inhibits tau aggregation by a mechanism involving preferential associations with soluble, monomeric, and prefibrillar oligomeric tau species; (5) HSP70 upregulates the expression of insulin degrading enzyme (IDE) and TGF-β, which enhance the clearance of Aβ.

3.5. HSP70: A Therapeutical Strategy for AD?

HSP70 as one of major molecular chaperones not only participates in the cellular protein quality control and degradation systems, but also implicates the neuroprotective response to pathological manifestations of AD [6, 11, 32, 48]. On the basis of those dramatic functions, HSP70 has increasingly attracted researchers’ attention. At present, there are four main therapeutic strategies to treat AD by characteristic HSP70’s functions mentioned above: induction endogenous of HSP70, utilization exogenous HSP70, efforts to differing levels of constitutively expressed HSP70, and utilization inhibitor of HSP70 ATPase.

3.6. Induction Endogenous of HSP70

Efforts to promote endogenous HSP70 synthesis induced in many different conditions could be therapeutically relevant for AD. Initially, induction of HSP70 during heat shock protected against AD-like hyperphosphorylation of tau in PC12 cells was reported [53]. Subsequently, induction of HSP70 by geldanamycin suppresses formation of neurofibrillary tangles by partitioning tau into a productive folding pathway and thereby preventing tau aggregation in COS-1 cells was identified [42]. Therefore, the neuroprotective effect of HSP70 in AD has received extensive attention. Based on above experimental results, YC-1 [3-(50-hydroxymethyl-20-furyl)-1-benzylindazole] was used to induce HSP70 expression, which prevented Aβ-induced cytotoxicity in PC12 cells [54]. Overexpression of HSP70 achieved by transfecting neurons with HSP70-expression plasmids significantly protects against etoposide, C2-ceramide, staurosporine, and Aβ (25–35)-induced neuronal apoptosis [52].

New advances in high throughput screening (HTS) methodology are rapidly changing the landscape of discovery in induction of HSP70. The finding that estrogen may facilitate HSP70 expression in different cells under various stress conditions was reported [55]. Recently, Hirakawa et al. indicated that HSP70 played a role in DNA protection mediated by estrogen, and the DNA protection might be involved in AD preventive effect from estrogen. Geranylgeranylacetone (GGA) has been widely considered as a nontoxic HSP-inducer although it is famous as a leading antiulcer drug [56]. Its cytoprotective, anti-inflammatory, and antiaggregation activities and induction of HSP70 expression were confirmed in animal models of various diseases. Hoshino et al. examined the effect of GGA on AD phenotypes exhibited by APP23 mice. They proposed that GGA should be considered as a candidate drug for the prevention of AD [9]. Curcumin elevated HSP90 and one of HSP70 subcellular compartments without increasing HSP mRNAs and reduced soluble tau, which showed that even after tangles had formed, tau-dependent behavioral and synaptic deficits could be corrected [57]. Celastrol is effective in inducing a set of neuroprotective HSPs in cultures derived from cerebral cortices, including HSP70, HSP27, and HSP32. It is deemed as a potential agent to counter AD [58]. Drugs mentioned above not only develop new leads for therapeutic development in AD, but also discover new chemical probes for use in understanding HSP70 biology.

3.7. Utilization Exogenous HSP70

Another potential remedy for AD is utilization of exogenous HSP70. Recently, intranasally administered HSP70 rapidly enters the afflicted brain regions and mitigates multiple AD-like morphological and cognitive abnormalities observed in model animals [12]. However, a long-lasting effect of exogenous HSP70 cannot be readily explained by its direct chaperone activity against misfolded AD proteins, or by indirect effects, such as the suppression of apoptosis and HSP70-mediated autophagy. Recent findings suspected that exogenous HSP70 could stimulate the innate immune response and significantly reduce the level of reactive oxygen species [59, 60].

3.8. Efforts to Differing Levels of Constitutively Expressed HSP70

Previous reports have shown that HSP70 includes the primary cytosolic variants, HSC70 and HSP72, and influenced tau conformation, degradation, and aggregation kinetics [61]. Some studies suggested that overexpression of HSP70 variants can facilitate tau clearance, whereas others suggested the opposing activities of HSP70 variants that HSC70 may preserve tau in a more unstructured state, perhaps facilitating its pathogenicity. Hence, using tetracycline- (Tet-) based protein chase HEK cell model to make clear these differences between HSC70 and HSP72 with regard to tau clearance. These findings suggested that HSP72 and HSC70 caused distinct and even opposing effects on tau’s function and stability even if their sequences are similar. HSP72 was confirmed to accelerate tau clearance while HSC70 slows it [62]. A delicate expression level of HSP70 variants must be managed to prevent tau from accumulating to the point of being neurotoxic. Efforts to promote HSP72 expression and inhibit HSP70 could be therapeutically relevant for AD [62].

3.9. Utilization Inhibitor of HSP70 ATPase

Inhibitors of the ATPase activity of HSP70 also come into people’s line of sight because of their function as mentioned above. Methylene blue (MB), a recently described inhibitor of HSP70 ATPase, not only was shown to favor tau turnover but also was able to facilitate keeping tau homeostasis [63]. However, MB is the first generation compounds and is not selective for HSP70. MKT-077 also is one of known HSP70 inhibitors, which are HSP70 selective in cells and cannot pass the blood-brain barrier (BBB). Together these problems have limited use of MB and MKT-077 as clinical treatment. Very recently synthetic YM-08 as a neutral analogue of MKT-077 retained affinity for HSP70 in vitro and selectively reduced pathogenic tau in brain. Thus, YM-08 may serve as a suitable chemical for further development as a CNS penetrant HSP70 inhibitor [64] (Figure 2).

Figure 2: HSP70 as a therapeutic strategy for AD. Endogenous stimulus and exogenous utilization elevate the level of HSP70, which inhibit the cytotoxicity of Aβ, tauopathy in brain, and apoptosis in AD. Efforts to promote HSP72 expression and inhibit HSC70 could accelerate tau clearance, which attenuate tauopathy. Inhibitors of the ATPase activity of HSP70 reduced pathogenic tau in brain.

4. Conclusions

There are numerous convincing reports to illustrate HSP70 and related compounds associate with AD pathogenesis. As mentioned previously, a large amount of evidence indicates HSP70 and related compounds have remarkable neuroprotective effects in several models of AD both in vivo and in vitro. These mechanisms between HSP70 and those pathological features of AD provoked a lot of interest to explore curing strategies. Although much evidence exists for a positive effect of HSP70 in animal and cellular models of AD, some limitations must be overcome before a therapeutic use for these proteins is established: (1) the present findings were mainly confirmed by cellular and animal experiments in AD; (2) the mode of action also was proven in different cellular and animal models of AD; and (3) some effect of increased synthesis induction of HSP70 is unpredictable, because quantitative control of the amount of HSP70 useful for a therapeutic response is difficult to determine. On the whole, further studies will be required to fully elucidate the roles of HSP70 in AD.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (81000544, 81171209, and 81371406) and Shandong Provincial Natural Science Foundation, China (ZR2010HQ004 and ZR2011HZ001).

References

R. Brookmeyer, E. Johnson, K. Ziegler-Graham, and H. M. Arrighi, “Forecasting the global burden of Alzheimer's disease,” Alzheimer's & Dementia, vol. 3, no. 3, pp. 186–191, 2007.

W. Thies and L. Bleiler, “2013 Alzheimer's disease facts and figures,” Alzheimer's & Dementia, vol. 9, no. 2, pp. 208–245, 2013.

S. Paul and S. Mahanta, “Association of heat-shock proteins in various neurodegenerative disorders: is it a master key to open the therapeutic door?” Molecular and Cellular Biochemistry, vol. 386, no. 1-2, pp. 45–61, 2014.

A. B. Meriin and M. Y. Sherman, “Role of molecular chaperones in neurodegenerative disorders,” International Journal of Hyperthermia, vol. 21, no. 5, pp. 403–419, 2005.

T. B. Franklin, A. M. Krueger-Naug, D. B. Clarke, A.-P. Arrigo, and R. W. Currie, “The role of heat shock proteins Hsp70 and Hsp27 in cellular protection of the central nervous system,” International Journal of Hyperthermia, vol. 21, no. 5, pp. 379–392, 2005.

J. Magrané, R. C. Smith, K. Walsh, and H. W. Querfurth, “Heat shock protein 70 participates in the neuroprotective response to intracellularly expressed beta-amyloid in neurons,” Journal of Neuroscience, vol. 24, no. 7, pp. 1700–1706, 2004.

B. Bukau and A. L. Horwich, “The Hsp70 and Hsp60 chaperone machines,” Cell, vol. 92, no. 3, pp. 351–366, 1998.

S. M. Doyle, O. Genest, and S. Wickner, “Protein rescue from aggregates by powerful molecular chaperone machines,” Nature Reviews Molecular Cell Biology, vol. 14, no. 10, pp. 617–629, 2013.

T. Hoshino, N. Murao, T. Namba et al., “Suppression of Alzheimer's disease-related phenotypes by expression of heat shock protein 70 in mice,” Journal of Neuroscience, vol. 31, no. 14, pp. 5225–5234, 2011.

P. J. Muchowski and J. L. Wacker, “Modulation of neurodegeneration by molecular chaperones,” Nature Reviews Neuroscience, vol. 6, no. 1, pp. 11–22, 2005.

C. G. Evans, S. Wisén, and J. E. Gestwicki, “Heat shock proteins 70 and 90 inhibit early stages of amyloid β-(1-42) aggregation in vitro,” The Journal of Biological Chemistry, vol. 281, no. 44, pp. 33182–33191, 2006.

N. V. Bobkova, D. G. Garbuz, I. Nesterova et al., “Therapeutic effect of exogenous Hsp70 in mouse models of Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 38, no. 2, pp. 425–435, 2014.

F. U. Hartl, A. Bracher, and M. Hayer-Hartl, “Molecular chaperones in protein folding and proteostasis,” Nature, vol. 475, no. 7356, pp. 324–332, 2011.

S. V. Slepenkov and S. N. Witt, “The unfolding story of the Escherichia coli Hsp70 DnaK: is DnaK a holdase or an unfoldase?” Molecular Microbiology, vol. 45, no. 5, pp. 1197–1206, 2002.

C. Huang, J. Wang, Z. Chen, Y. Wang, and W. Zhang, “2-phenylethynesulfonamide prevents induction of pro-inflammatory factors and attenuates LPS-induced liver injury by targeting NHE1-Hsp70 complex in mice,” PLoS ONE, vol. 8, no. 6, Article ID e67582, 2013.

G. R. Luo and W. D. Le, “Collective roles of molecular chaperones in protein degradation pathways associated with neurodegenerative diseases,” Current Pharmaceutical Biotechnology, vol. 11, no. 2, pp. 180–187, 2010.

J. Tyedmers, A. Mogk, and B. Bukau, “Cellular strategies for controlling protein aggregation,” Nature Reviews Molecular Cell Biology, vol. 11, no. 11, pp. 777–788, 2010.

E. R. P. Zuiderweg, E. B. Bertelsen, A. Rousaki, M. P. Mayer, J. E. Gestwicki, and A. Ahmad, “Allostery in the Hsp70 chaperone proteins,” Topics in Current Chemistry, vol. 328, pp. 99–153, 2013.

E. B. Bertelsena, L. Chang, J. E. Gestwicki, and E. R. P. Zuiderweg, “Solution conformation of wild-type E. coli Hsp70 (DnaK) chaperone complexed with ADP and substrate,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 21, pp. 8471–8476, 2009.

P. Bork, C. Sander, and A. Valencia, “An ATPase domain common to prokaryotic cell cycle proteins, sugar kinases, actin, and hsp70 heat shock proteins,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 16, pp. 7290–7294, 1992.

E. Schaffitzel, S. Rüdiger, B. Bukau, and E. Deuerling, “Functional dissection of trigger factor and DnaK: interactions with nascent polypeptides and thermally denatured proteins,” Biological Chemistry, vol. 382, no. 8, pp. 1235–1243, 2001.

J. Frydman, “Folding of newly translated proteins in vivo: the role of molecular chaperones,” Annual Review of Biochemistry, vol. 70, pp. 603–648, 2001.

W. B. Pratt and D. O. Toft, “Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery,” Experimental Biology and Medicine, vol. 228, no. 2, pp. 111–133, 2003.

J. C. Young, J. M. Barral, and F. U. Hartl, “More than folding: localized functions of cytosolic chaperones,” Trends in Biochemical Sciences, vol. 28, no. 10, pp. 541–547, 2003.

B. Bercovich, I. Stancovski, A. Mayer et al., “Ubiquitin-dependent degradation of certain protein substrates in vitro requires the molecular chaperone Hsc70,” The Journal of Biological Chemistry, vol. 272, no. 14, pp. 9002–9010, 1997.

G. Turturici, G. Sconzo, and F. Geraci, “Hsp70 and its molecular role in nervous system diseases,” Biochemistry Research International, vol. 2011, Article ID 618127, 18 pages, 2011.

F. U. Hartl and M. Hayer-Hartl, “Molecular chaperones in the cytosol: from nascent chain to folded protein,” Science, vol. 295, no. 5561, pp. 1852–1858, 2002.

B. Bukau, J. Weissman, and A. Horwich, “Molecular chaperones and protein quality control,” Cell, vol. 125, no. 3, pp. 443–451, 2006.

S. A. Broadley and F. U. Hartl, “The role of molecular chaperones in human misfolding diseases,” FEBS Letters, vol. 583, no. 16, pp. 2647–2653, 2009.

M. E. Murphy, “The HSP70 family and cancer,” Carcinogenesis, vol. 34, no. 6, pp. 1181–1188, 2013.

S. N. Witt, “Hsp70 molecular chaperons and Parkinson's disease,” Biopolymers, vol. 93, no. 3, pp. 218–228, 2010.

P. Kumar, R. K. Ambasta, V. Veereshwarayya et al., “CHIP and HSPs interact with β-APP in a proteasome-dependent manner and influence Aβ metabolism,” Human Molecular Genetics, vol. 16, no. 7, pp. 848–864, 2007.

G. M. Shankar, S. Li, T. H. Mehta et al., “Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory,” Nature Medicine, vol. 14, no. 8, pp. 837–842, 2008.

K. Honjo, S. E. Black, and N. P. L. G. Verhoeff, “Alzheimer's disease, cerebrovascular disease, and the β-amyloid cascade,” Canadian Journal of Neurological Sciences, vol. 39, no. 6, pp. 712–728, 2012.

K. Herrup, “Reimagining Alzheimer's disease—an age-based hypothesis,” Journal of Neuroscience, vol. 30, no. 50, pp. 16755–16762, 2010.

J. A. Hardy and G. A. Higgins, “Alzheimer's disease: The amyloid cascade hypothesis,” Science, vol. 256, no. 5054, pp. 184–185, 1992.

S. Oddo, A. Caccamo, J. D. Shepherd et al., “Triple-transgenic model of Alzheimer's Disease with plaques and tangles: Intracellular Aβ and synaptic dysfunction,” Neuron, vol. 39, no. 3, pp. 409–421, 2003.

K. R. Patterson, C. Remmers, Y. Fu et al., “Characterization of prefibrillar tau oligomers in vitro and in Alzheimer disease,” The Journal of Biological Chemistry, vol. 286, no. 26, pp. 23063–23076, 2011.

A. Sydow, A. Van Der Jeugd, F. Zheng et al., “Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic tau mutant,” Journal of Neuroscience, vol. 31, no. 7, pp. 2511–2525, 2011.

E. D. Roberson, B. Halabisky, J. W. Yoo et al., “Amyloid-β/fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of alzheimer's disease,” Journal of Neuroscience, vol. 31, no. 2, pp. 700–711, 2011.

S. M. Ward, D. S. Himmelstein, J. K. Lancia, and L. I. Binder, “Tau oligomers and tau toxicity in neurodegenerative disease,” Biochemical Society Transactions, vol. 40, no. 4, pp. 667–671, 2012.

F. Dou, W. J. Netzer, K. Tanemura et al., “Chaperones increase association of tau protein with microtubules,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 2, pp. 721–726, 2003.

H. Shimura, D. Schwartz, S. P. Gygi, and K. S. Kosik, “CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival,” The Journal of Biological Chemistry, vol. 279, no. 6, pp. 4869–4876, 2004.

L. Petrucelli, D. Dickson, K. Kehoe et al., “CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation,” Human Molecular Genetics, vol. 13, no. 7, pp. 703–714, 2004.

U. K. Jinwal, J. C. O'Leary III, S. I. Borysov et al., “Hsc70 rapidly engages tau after microtubule destabilization,” The Journal of Biological Chemistry, vol. 285, no. 22, pp. 16798–16805, 2010.

Y. Miyata, J. Koren III, J. Kiray, C. A. Dickey, and J. E. Gestwicki, “Molecular chaperones and regulation of tau quality control: Strategies for drug discovery in tauopathies,” Future Medicinal Chemistry, vol. 3, no. 12, pp. 1523–1537, 2011.

Y. Wang, M. Martinez-Vicente, U. Kruger et al., “Synergy and antagonism of macroautophagy and chaperone-mediated autophagy in a cell model of pathological tau aggregation,” Autophagy, vol. 6, no. 1, pp. 182–183, 2010.

K. R. Patterson, S. M. Ward, B. Combs et al., “Heat shock protein 70 prevents both tau aggregation and the inhibitory effects of preexisting tau aggregates on fast axonal transport,” Biochemistry, vol. 50, no. 47, pp. 10300–10310, 2011.

U. K. Jinwal, Y. Miyata, J. Koren III et al., “Chemical manipulation of Hsp70 ATPase activity regulates tau stability,” Journal of Neuroscience, vol. 29, no. 39, pp. 12079–12088, 2009.

R. J. S. Viana, C. J. Steer, and C. M. P. Rodrigues, “Amyloid-β peptide-induced secretion of endoplasmic reticulum chaperone glycoprotein GRP94,” Journal of Alzheimer's Disease, vol. 27, no. 1, pp. 61–73, 2011.

C. Mailhos, M. K. Howard, and D. S. Latchman, “Heat shock proteins hsp90 and hsp70 protect neuronal cells from thermal stress but not from programmed cell death,” Journal of Neurochemistry, vol. 63, no. 5, pp. 1787–1795, 1994.

B. Sabirzhanov, B. A. Stoica, M. Hanscom, C.-S. Piao, and A. I. Faden, “Over-expression of HSP70 attenuates caspase-dependent and caspase-independent pathways and inhibits neuronal apoptosis,” Journal of Neurochemistry, vol. 123, no. 4, pp. 542–554, 2012.

B. A. Kirby, C. R. Merril, H. Ghanbari, and W. C. Wallace, “Heat shock proteins protect against stress-related phosphorylation of tau in neuronal PC12 cells that have acquired thermotolerance,” Journal of Neuroscience, vol. 14, no. 9, pp. 5687–5693, 1994.

Y.-C. Tsai, Y.-M. Lee, K.-K. Lam et al., “The role of heat shock protein 70 in the protective effect of YC-1 on beta-amyloid-induced toxicity in differentiated PC12 cells,” PLoS ONE, vol. 8, no. 7, Article ID e69320, 2013.

T. Al-Khlaiwi, A. Al-Drees, E. Gursoy, I. Qureshi, T. Biber, and M. Kalimi, “Estrogen protects cardiac myogenic (H9c2) rat cells against lethal heat shock-induced cell injury: Modulation of estrogen receptor α, glucocorticoid receptors, heat shock protein 70, and iNOS,” Journal of Cardiovascular Pharmacology, vol. 45, no. 3, pp. 217–224, 2005.

T. Hirakawa, K. Rokutan, T. Nikawa, and K. Kishi, “Geranylgeranylacetone induces heat shock proteins in cultured guinea pig gastric mucosal cells and rat gastric mucosa,” Gastroenterology, vol. 111, no. 2, pp. 345–357, 1996.

Q.-L. Ma, X. Zuo, F. Yang et al., “Curcumin suppresses soluble Tau dinners and corrects molecular chaperone, synaptic, and behavioral deficits in aged human Tau transgenic mice,” The Journal of Biological Chemistry, vol. 288, no. 6, pp. 4056–4065, 2013.

A. M. Chow, D. W. F. Tang, A. Hanif, and I. R. Brown, “Induction of heat shock proteins in cerebral cortical cultures by celastrol,” Cell Stress and Chaperones, vol. 18, no. 2, pp. 155–160, 2013.

J. D. Johnson and M. Fleshner, “Releasing signals, secretory pathways, and immune function of endogenous extracellular heat shock protein 72,” Journal of Leukocyte Biology, vol. 79, no. 3, pp. 425–434, 2006.

M. Vinokurov, V. Ostrov, M. Yurinskaya et al., “Recombinant human Hsp70 protects against lipoteichoic acid-induced inflammation manifestations at the cellular and organismal levels,” Cell Stress and Chaperones, vol. 17, no. 1, pp. 89–101, 2012.

S. B. Goldfarb, O. B. Kashlan, J. N. Watkins et al., “Differential effects of Hsc70 and Hsp70 on the intracellular trafficking and functional expression of epithelial sodium channels,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 15, pp. 5817–5822, 2006.

U. K. Jinwal, E. Akoury, J. F. Abisambra et al., “Imbalance of Hsp70 family variants fosters tau accumulation,” FASEB Journal, vol. 27, no. 4, pp. 1450–1459, 2013.

J. C. O'Leary, Q. Li, P. Marinec et al., “Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden,” Molecular Neurodegeneration, vol. 5, no. 1, article 45, 2010.

Y. Miyata, X. Li, H.-F. Lee et al., “Synthesis and initial evaluation of YM-08, a blood-brain barrier permeable derivative of the heat shock protein 70 (Hsp70) inhibitor MKT-077, which reduces tau levels,” ACS Chemical Neuroscience, vol. 4, no. 6, pp. 930–939, 2013.